Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.

导出 OA

翻译打印收藏纠错

作者： Myriam M,Ouberai ^[1] ; Ana L Gomes,Dos Santos ^[2] ; Sonja,Kinna ^[1] ; Shimona,Madalli ^[3] ; David C,Hornigold ^[3] ; David,Baker ^[3] ; Jacqueline,Naylor ^[3] ; Laura,Sheldrake ^[4] ; Dominic J,Corkill ^[5] ; John,Hood ^[6] ; Paolo,Vicini ^[6] ; Shahid,Uddin ^[2] ; Steven,Bishop ^[7] ; Paul G,Varley ^[2] ; Mark E,Welland ^[8]

作者单位： Nanoscience Centre, Department of Engineering, University of Cambridge, Cambridge, CB3 0FF, UK. ^[1] Biopharmaceutical Development, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. ^[2] Cardiovascular and Metabolic Diseases, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. ^[3] Invivo Sciences UK, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. ^[4] Respiratory, Inflammation and Autoimmunity, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. ^[5] Clinical Pharmacology, Drug Metabolism and Pharmacokinetics, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. ^[6] Biopharmaceutical development, MedImmune LLC Gaithersburg Headquarters, One MedImmune Way, Gaithersburg, MD, 20878, USA. ^[7] Nanoscience Centre, Department of Engineering, University of Cambridge, Cambridge, CB3 0FF, UK. mew10@cam.ac.uk. ^[8]